Evaxion Biotech announces financing commitments up to $20M

Evaxion Biotech has entered into a binding agreement for a financing of up to USD 20 million with Negma Group Investment Ltd, a Paris-based leading financial institution focused on supporting growth and capturing value through a multi-strategy approach. Financing is available in tranches of up to USD 700,000 over a period of 36 months. Executing individual tranches and the timing of such tranches is at the discretion of Evaxion subject to certain terms and conditions. The convertible bonds carry a zero coupon and will be issued at a subscription price corresponding to their par value. The conversion price will be determined as 83.5% of the second lowest closing volume weighted average share price of at least 8 trading days immediately preceding the issuance of each conversion request by Negma. The financing commitments are intended to cover the Company’s working capital needs, including the ongoing clinical phase 2 trial of EVX-01, and the advancement of EVX-03 towards the initiation of a Phase 1 clinical trial. If Evaxion fully utilizes the convertible note program, the company will have sufficient financing to fund its planned activities into Q4 2024. Evaxion plans to announce the interim results of the clinical Phase 2 study with EVX-01 in patients with metastatic melanoma in Q4 2023, a program where promising Phase 1/2a data were presented at ASCO in June 2023. In addition, the Company plans to initiate a Phase 1 clinical trial with EVX-03 in patients with lung cancer and other solid tumors. EVX-03 is based on the use of Evaxion’s proprietary AI-technology and novel ObsERV platform, which enables the Company to identify new patient-specific tumor targets called ERVs to enhance the efficacy of its personalized cancer vaccines, with potential to broaden the utility to patients unresponsive to current immunotherapies.